FFO
IMRX icon

Fortitude Family Office’s Immuneering IMRX Stock Holding History

Fortitude Family Office’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-105
Closed -$553 – 2321
2026
Q1 		$553 Buy
+105
New +$538 ﹤0.01% 1688

Other funds holding IMRX

PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
FCC
Flower City Capital Pittsford, New York $227M AUM 23.31% 1-Year Est. Return
BM
Berman McAleer Timonium, Maryland $864M AUM 22.02% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $2.09B AUM 34.27% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
FFN
Focus Financial Network Minneapolis, Minnesota $3.23B AUM 29.61% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Fortitude Family Office's IMRX Position: Q2 2026 in Review

Fortitude Family Office sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 105 shares — an estimated $553 sold.

Fortitude Family Office first reported a position in IMRX in Q1 2026 and held it in 1 quarter. The position peaked at $553 in Q1 2026. 11 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Fortitude Family Office reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 105 Immuneering shares in Q2 2026, an estimated $553.
  • Fortitude Family Office first reported a position in Immuneering in Q1 2026 and held it in 1 quarter.
  • Fortitude Family Office's Immuneering position peaked at $553 in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.